[Combination treatment of late nasopharyngeal carcinoma: an analysis of short-term therapeutic results in 200 cases].
Patients with late nasopharyngeal carcinoma (NPC) were divided into 4 groups, 50 each, treated with different protocols. Group A: radiotherapy plus systemic interlenkin 2 (IL-2), Group B: chemotherapy plus radiotherapy, Group C: chemotherapy plus radiation and IL-2, Group D: radiotherapy alone. Changes in the primary tumor and neck lymph nodes were monitored at 0, 3 and 6 months after treatment. In group A, the primary tumor regression rates (TRR) were 88%, 90% and 92%, and the lymph nodes regression rates (LNR) were 82%, 86% and 88%, respectively. In group B, the TRR were 86%, 88% and 90%, and the LNR were 80%, 84% and 86%, respectively. In group C, the TRR were 88%, 90% and 92%, and the LNR were 82%, 86% and 88%, respectively. In group D, the TRR were 78% 80% and 82%, and the LNR were 76%, 78% and 80%, respectively. The 1-year survival rates in these 4 groups of patients were 92%, 90%, 94% and 82%, respectively. Thus, the therapeutic results are significantly better in the combination treatment groups than those in the group receiving radiotherapy alone. In addition, IL-2 was effective to significantly reduce the occurrence of systemic side effects of radiotherapy and radiotherapy plus chemotherapy.
Zhang
S
S
First People's Hospital of Zhaoqing City, Guangdong.
Cai
Y
Y
Gu
Y
Y
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001761:Bleomycin / Q000008:administration & dosage; D002294:Carcinoma, Squamous Cell / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009303:Nasopharyngeal Neoplasms / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D011882:Radiotherapy, High-Energy
D007376:Interleukin-2; D001761:Bleomycin; D002945:Cisplatin; D005472:Fluorouracil